StockNews.AI
DAWN
StockNews.AI
119 days

Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025

1. Day One Biopharmaceuticals will report Q1 2025 financials on May 6. 2. The company focuses on targeted therapies for pediatric cancer. 3. Current pipeline includes tovorafenib, DAY301, and a VRK1 inhibitor. 4. Day One aims to improve cancer drug development from diagnosis. 5. A live webcast of the conference will be available for replay.

4m saved
Insight
Article

FAQ

Why Bullish?

Upcoming financial results could show progress in pipeline, boosting confidence in DAWN.

How important is it?

The upcoming earnings report is critical for investor sentiment and pipeline development updates.

Why Short Term?

Financial results typically impact stock prices shortly after being released, as seen in past earnings reports.

Related Companies

N/A
April 22, 2025 08:30 ET  | Source: Day One Biopharmaceuticals, Inc. BRISBANE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, May 6, 2025 at 4:30 p.m. ET to report financial results and discuss corporate progress for the first quarter 2025. Live audio of the webcast will be accessible on the Day One Investors & Media page. An archived version of the webcast will be available for replay on the Events & Presentations section of the Day One Investors & Media page for 30 days following the event. About Day One BiopharmaceuticalsDay One Biopharmaceuticals believes when it comes to pediatric cancer, we can do better. The Company was founded to address a critical unmet need: the dire lack of therapeutic development in pediatric cancer. Inspired by “The Day One Talk” that physicians have with patients and their families about an initial cancer diagnosis and treatment plan, Day One aims to re-envision cancer drug development and redefine what’s possible for all people living with cancer—regardless of age—starting from day one. Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important targeted cancer treatments. The Company’s pipeline includes tovorafenib (OJEMDA™), DAY301 and a VRK1 inhibitor program. Day One is based in Brisbane, California. For more information, please visit www.dayonebio.com or find the Company on LinkedIn or X. Day One uses its Investor Relations website (ir.dayonebio.com), its X handle (x.com/DayOneBio), and LinkedIn Home Page (linkedin.com/company/dayonebio) as a means of disseminating or providing notification of, among other things, news or announcements regarding its business or financial performance, investor events, press releases, and earnings releases, and as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. DAY ONE MEDIALaura Cooper, Head of Communicationsmedia@dayonebio.com DAY ONE INVESTORSLifeSci Advisors, PJ Kelleherpkelleher@lifesciadvisors.com

Related News